Healthcare company Perrigo Company plc (NYSE:PRGO) (TASE:PRGO) disclosed on Wednesday the receipt of the tentative approval from the US Food and Drug Administration for the generic version of Prolensa (bromfenac ophthalmic solution) 0.07% for treating ocular pain in patients.
In conjunction with the US FDA's tentative approval,the company has settled litigation with Bausch & Lomb Inc for Prolensa (bromfenac ophthalmic solution) 0.07%.
According to the company, Prolensa (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
For the last 12 months, the branded market sales of Prolensa Ophthalmic Solution 0.07% were approximately USD113m, concluded the company.
Dr. Reddy's Laboratories unveils Chlorthalidone Tablets, USP in the US market
Perrigo awarded US FDA tentative approval for first to file generic Ultravate Lotion 0.05%
Indivior PLC unveils PERSERIS once-monthly in the US antipsychotic market
Armas Pharmaceuticals to launch Azacitidine for Injection 100 MG in US
Nexus Pharmaceuticals Receives FDA Approval for Arsenic Trioxide Injection in 10mg per 10mL Vial
Nexus Pharmaceuticals introduces Arsenic Trioxide Injection 10mg per 10mL vial in US
Dr. Reddy's Laboratories unveils Atomoxetine Capsules, USP in the US Market
Mayne Pharma acquires US and Australian rights to halobetasol foam 0.05%
Fresenius Kabi Introduces Leukemia Drug Arsenic Trioxide Injection in 10 mg per 10 mL vial
Breckenridge wins final US FDA approval for Clobazam Tablets ANDA
Teva Formalises North America Headquarters Move with Ceremony in Israel
Amneal to unveil generic Isoproterenol Hydrochloride Injection USP in the US